Cordance Medical

Cover Block

Field	Value
Name	Cordance Medical
Tagline	Noninvasive focused ultrasound platform to open the blood-brain barrier for brain disease treatments
Headquarters	Mountain View, California, United States
Founded	2018
Stage	Seed
Business Model	Hardware + Software (medical device)
Industry	Healthtech / Medical Devices
Technology Type	Hardware (focused ultrasound)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed
Total Disclosed	~$8,000,000 [PRNewswire, November 2025]

Links

• Website: https://cordancemedical.com/
• LinkedIn: https://www.linkedin.com/company/cordance-medical

What an Investor Needs First

Cordance Medical is a Mountain View-based medical device company developing NeuroAccess, a noninvasive focused ultrasound system designed to transiently open the blood-brain barrier (BBB) so that diagnostics and therapeutics can reach brain tissue that is otherwise pharmacologically unreachable [Cordance Medical, November 2025]. The company was founded in 2018 by Bhaskar Ramamurthy, an ultrasound engineer with prior roles at Acuson, Siemens, Innervision, and SRI International, and is now run day-to-day by CEO Ryan Dittamore, formerly Chief Business Officer of Decipher Biosciences (acquired by Veracyte for $600M) [Cordance Medical; Crunchbase]. NeuroAccess received FDA Breakthrough Device Designation in October 2023 for enabling liquid biopsy in brain tumors using focused ultrasound and microbubbles [Medical Product Outsourcing, October 2023]. In November 2025, Cordance closed an oversubscribed $8M seed round led by Sonder Capital, with participation from Shanda Grab Ventures, Angel Physician's Fund, SmartGateVC, and R42 [PRNewswire, November 2025]. Preclinical work with EXACT Therapeutics in glioblastoma mouse models reported a 127 to 145 percent increase in radiopharmaceutical uptake when paired with NeuroAccess [PRNewswire, February 2025]. The investable thesis is that Cordance is positioning a hardware platform at the intersection of two large unmet needs (brain tumor diagnostics and CNS drug delivery) where the dominant incumbent, Insightec, is focused primarily on therapeutic ablation rather than BBB opening for biopsy. Over the next 12 to 18 months, watch for sonobiopsy clinical readouts in high-grade glioma, expansion of the EXACT Therapeutics partnership into in-vivo dose escalation, and any partnership announcements with large pharma developing brain-penetrant biologics.

Data Accuracy: GREEN -- Confirmed by Cordance Medical, PRNewswire, Medical Product Outsourcing, and Crunchbase.

Taxonomy Snapshot

Axis	Value
Stage	Seed (closed November 2025)
Business Model	Hardware device with software-guided treatment planning
Industry / Vertical	Medical devices, neuro-oncology, CNS drug delivery
Technology Type	Focused ultrasound + microbubble BBB opening
Geography	Headquartered United States; clinical reach North America
Growth Profile	Venture scale, regulated medical device timeline
Founding Team	Solo founder (Bhaskar Ramamurthy), separate operating CEO
Funding	~$8M total disclosed [PRNewswire, November 2025]

Inside the Company

Cordance Medical was founded in 2018 by Bhaskar Ramamurthy, PhD, a long-time ultrasound engineer whose prior career at Acuson, Siemens, Innervision, and SRI International centered on diagnostic ultrasound imaging [Focused Ultrasound Foundation; Cordance Medical]. The thesis behind the company is that focused ultrasound, when paired with intravenous microbubbles, can mechanically and reversibly open the blood-brain barrier in a targeted region of the brain for a window of several hours, allowing molecules that would otherwise be excluded to cross the barrier [Cordance Medical, Our Solution]. The company is headquartered at 2483 Old Middlefield Way, Suite 120, Mountain View, California [Cordance Medical, Contact].

The most consequential milestone to date is the October 2023 FDA Breakthrough Device Designation for the NeuroAccess platform, granted specifically for enabling liquid biopsy in brain tumors [Medical Product Outsourcing, October 2023; Neurosurgery News International]. That designation followed a first-in-human prospective sonobiopsy trial in high-grade glioma patients using neuronavigation-guided focused ultrasound, the results of which were published in npj Precision Oncology in 2023 [Cordance Medical Publications]. In February 2025, Cordance and Norway-based EXACT Therapeutics announced encouraging preclinical data showing that NeuroAccess increased radiopharmaceutical uptake in glioblastoma mouse models by between 127 and 145 percent versus control [PRNewswire, February 2025; Yahoo Finance, February 2025]. The November 2025 oversubscribed $8M seed financing led by Sonder Capital is the company's first publicly disclosed institutional round [PRNewswire, November 2025].

Data Accuracy: GREEN -- Confirmed by Cordance Medical, PRNewswire, Medical Product Outsourcing, and Focused Ultrasound Foundation.

Under the Hood

The core product is NeuroAccess, a noninvasive focused ultrasound device designed to temporarily open the blood-brain barrier at a clinician-defined target inside the brain [Cordance Medical, Our Solution]. The mechanism combines low-intensity ultrasound energy with intravenously administered microbubbles; the bubbles oscillate within the targeted vasculature and produce a transient, reversible loosening of the tight junctions in the BBB without thermal ablation [Cordance Medical, The Blood-Brain Barrier]. NeuroAccess uses neuronavigation guidance, meaning the treatment is co-registered to the patient's MRI so that the energy can be steered to a specific tumor or anatomical region [Cordance Medical Publications].

Two applications anchor the near-term commercial story. The first is sonobiopsy, in which BBB opening is used to release tumor-derived nucleic acids and proteins into the systemic circulation where they can be sampled by a peripheral blood draw [Cordance Medical, October 2023]. This is the indication that earned FDA Breakthrough Device Designation in October 2023 [Medical Product Outsourcing, October 2023]. The second is enhanced therapeutic delivery, where NeuroAccess opens the BBB immediately before or during dosing of a systemically administered drug. The EXACT Therapeutics collaboration is the clearest current evidence that this works in vivo, with reported radiopharmaceutical uptake increases of 127 to 145 percent in glioblastoma mouse models [PRNewswire, February 2025].

Data Accuracy: GREEN -- Confirmed by Cordance Medical, PRNewswire, and Medical Product Outsourcing.

Market Research and Opportunity

The blood-brain barrier excludes roughly 98 percent of small molecules and nearly all large-molecule biologics from the brain parenchyma, which is why decades of investment in Alzheimer's, glioblastoma, and Parkinson's disease have produced relatively few systemically delivered therapies that reach therapeutic concentrations at the target [Cordance Medical, The Blood-Brain Barrier].

Glioblastoma alone has roughly 12,000 to 13,000 newly diagnosed US cases per year and a five-year survival rate in the single digits, which is the population the FDA Breakthrough Device Designation directly addresses. Brain metastases occur in an estimated ten times that volume of cancer patients each year, primarily from lung, breast, and melanoma primaries. Adjacent markets include the radiopharmaceutical category and the broader CNS biologics pipeline, where every brain-penetrant antibody program is a potential combination partner for a BBB-opening platform.

Pharma is actively spending on brain-penetrant biologics; Roche, Eli Lilly, and Eisai have all advanced anti-amyloid programs in Alzheimer's that are limited in part by delivery efficiency. Insightec's Exablate Neuro device received FDA approval in 2016 for essential tremor and has subsequently obtained additional indications, demonstrating that focused ultrasound can clear the regulatory bar in brain applications [Insightec public disclosures].

Metric	Value
Cordance preclinical uptake increase, glioblastoma mouse model	+127 to +145%
FDA Breakthrough Device Designation (NeuroAccess, sonobiopsy)	Granted October 2023
Cordance seed financing	$8M, oversubscribed

Data Accuracy: YELLOW -- Cordance-specific data points confirmed by two or more sources; broader TAM context is contextual rather than from a named third-party report.

Competition and Substitutes

Cordance is positioned as a focused, BBB-opening pure-play in a category where the leading public-company comparable, Insightec, has historically prioritized therapeutic ablation indications over BBB opening for diagnostics and drug delivery.

Company	Positioning	Stage / Funding	Notable Differentiator
Cordance Medical	Noninvasive focused ultrasound for BBB opening, lead indication sonobiopsy in brain tumors	Seed, ~$8M total	FDA Breakthrough Device Designation for liquid biopsy enablement
Insightec	MR-guided focused ultrasound for brain (essential tremor, Parkinson's tremor, BBB opening research)	Late-stage private, multiple FDA approvals on Exablate Neuro	Installed base of MR-guided systems at major academic centers

Data Accuracy: YELLOW -- Cordance positioning confirmed by multiple cited sources; competitor positioning sourced from public disclosures rather than direct comparison data.

Opportunity

If NeuroAccess works as advertised at clinical scale, Cordance is not a single-product device company; it is the enabling layer for an entire generation of brain-penetrant therapeutics and diagnostics. The headline opportunity is to become the default hardware platform that pharma partners with whenever a CNS drug needs help crossing the blood-brain barrier.

Scenario	What happens	Catalyst
Sonobiopsy standard of care	NeuroAccess becomes the routine alternative to surgical biopsy in inoperable brain tumors	Pivotal sonobiopsy trial readout in high-grade glioma
Pharma delivery platform	Multiple pharma partners license NeuroAccess as the BBB-opening companion to brain-penetrant biologics and radiopharmaceuticals	Second named pharma partnership beyond EXACT Therapeutics
Indication expansion	Platform extends from oncology into Alzheimer's and Parkinson's drug delivery	Investigator-initiated trials in neurodegenerative disease

Data Accuracy: GREEN -- Confirmed by PRNewswire, Medical Product Outsourcing, and Cordance Medical primary sources.

Sources

1. [Cordance Medical] Cordance Medical Homepage | https://cordancemedical.com/
2. [Cordance Medical] Our Solution | https://cordancemedical.com/our-solution/
3. [Cordance Medical] Team Members - Bhaskar Ramamurthy | https://cordancemedical.com/team-members/
4. [Cordance Medical] Eric Leuthardt, MD profile | https://cordancemedical.com/team-members/eric-leuthardt-md/
5. [Cordance Medical] The Blood-Brain Barrier | https://cordancemedical.com/the-problem/blood-brain-barrier/
6. [Cordance Medical] Brain Cancers | https://cordancemedical.com/the-problem/cancer/
7. [Cordance Medical] Contact Us | https://cordancemedical.com/contact-us/
8. [Cordance Medical, October 2023] NeuroAccess Receives FDA Breakthrough Device Designation for Liquid Biopsy in Brain Tumors | https://cordancemedical.com/cordance-medicals-neuroaccess-receives-fda-breakthrough-device-designation-for-liquid-biopsy-in-brain-tumors/
9. [Cordance Medical, November 2025] $8M Seed Financing Announcement | https://cordancemedical.com/cordance-medical-announces-an-oversubscribed-8m-seed-financing-to-advance-focused-ultrasound-platform-for-brain-disease-treatment/
10. [PRNewswire, November 2025] Cordance Medical Announces an Oversubscribed $8M Seed Financing | https://www.prnewswire.com/news-releases/cordance-medical-announces-an-oversubscribed-8m-seed-financing-to-advance-focused-ultrasound-platform-for-brain-disease-treatment-302624669.html
11. [PRNewswire, February 2025] Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model | https://finance.yahoo.com/news/cordance-medical-exact-therapeutics-announce-183600610.html
12. [Medical Product Outsourcing, October 2023] Cordance's Blood-Brain Barrier Opening Device Wins FDA Breakthrough Nod | https://www.mpo-mag.com/contents/view_breaking-news/2023-10-30/cordances-blood-brain-barrier-opening-device-wins-fda-breakthrough-nod
13. [Neurosurgery News International] Cordance gains US FDA breakthrough designation for NeuroAccess technology | https://neuronewsinternational.com/cordance-gains-us-fda-breakthrough-designation-for-neuroaccess-technology/
14. [Focused Ultrasound Foundation] Company Profile: Cordance Medical | https://www.fusfoundation.org/posts/company-profile-cordance-medical/
15. [Focused Ultrasound Foundation] FDA Grants Breakthrough Device Designation for Cordance Medical's Brain Tumor Liquid Biopsy Platform | https://www.fusfoundation.org/posts/fda-grants-breakthrough-device-designation-for-cordance-medicals-brain-tumor-liquid-biopsy-platform/
16. [Surgical Robotics Technology] Cordance Medical Reports an Oversubscribed $8M Seed Financing | https://www.surgicalroboticstechnology.com/news/cordance-medical-reports-an-oversubscribed-8m-seed-financing/
17. [Crunchbase] Cordance Medical company profile | https://www.crunchbase.com/organization/cordance-medical
18. [Crunchbase] Ryan Dittamore profile | https://www.crunchbase.com/person/ryan-dittamore
19. [Crunchbase] Bhaskar Ramamurthy profile | https://www.crunchbase.com/person/bhaskar-ramamurthy-8082
20. [PitchBook] Cordance Medical 2026 Company Profile | https://pitchbook.com/profiles/company/437326-84
21. [Tracxn] Cordance Medical company profile | https://tracxn.com/d/companies/cordance-medical/__k_3a5s9ez-Y-JeOF-IhCsFnr4NrBvvGF6yssQqGEmKA
22. [LinkedIn] Cordance Medical company page | https://www.linkedin.com/company/cordance-medical